$0.26 EPS Expected for Vertex Pharmaceuticals (VRTX); 5 Analysts Are Bullish Duke Energy (DUK) Last Week

April 19, 2018 - By Michael Collier

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Logo

Among 20 analysts covering Duke Energy (NYSE:DUK), 5 have Buy rating, 4 Sell and 11 Hold. Therefore 25% are positive. Duke Energy had 87 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Hold” rating by SunTrust given on Tuesday, January 16. The stock has “Neutral” rating by SunTrust on Monday, September 26. The rating was maintained by RBC Capital Markets with “Buy” on Sunday, August 27. Morgan Stanley maintained the stock with “Equal-Weight” rating in Monday, November 13 report. As per Monday, October 19, the company rating was maintained by Suntrust Robinson. SunTrust maintained the shares of DUK in report on Monday, March 5 with “Hold” rating. Citigroup maintained the shares of DUK in report on Wednesday, July 20 with “Neutral” rating. As per Wednesday, January 10, the company rating was downgraded by Goldman Sachs. Suntrust Robinson maintained the shares of DUK in report on Monday, August 29 with “Neutral” rating. The firm has “Buy” rating by Argus Research given on Tuesday, September 15. See Duke Energy Corporation (NYSE:DUK) latest ratings:

16/04/2018 Broker: SunTrust Rating: Hold New Target: $81.0000 Maintain
16/04/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $83 New Target: $85 Maintain
10/04/2018 Broker: JP Morgan Old Rating: Underweight New Rating: Underweight Old Target: $77 New Target: $78 Maintain
09/04/2018 Broker: SunTrust Rating: Hold New Target: $83.0000 Maintain
02/04/2018 Broker: SunTrust Rating: Hold New Target: $82.0000 Maintain
28/03/2018 Broker: Goldman Sachs Rating: Sell New Target: $78.0000 Downgrade
26/03/2018 Broker: SunTrust Rating: Hold New Target: $80.0000 Maintain
19/03/2018 Broker: SunTrust Rating: Hold New Target: $82.0 Maintain
14/03/2018 Broker: RBC Capital Markets Rating: Buy New Target: $90.0 Maintain
08/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $85 New Target: $83 Maintain

Analysts expect Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report $0.26 EPS on April, 26.They anticipate $0.13 EPS change or 100.00% from last quarter’s $0.13 EPS. VRTX’s profit would be $66.27M giving it 157.08 P/E if the $0.26 EPS is correct. After having $0.32 EPS previously, Vertex Pharmaceuticals Incorporated’s analysts see -18.75% EPS growth. The stock decreased 0.99% or $1.63 during the last trading session, reaching $163.36. About 970,020 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since April 19, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Investors sentiment increased to 1.13 in Q4 2017. Its up 0.06, from 1.07 in 2017Q3. It improved, as 46 investors sold Duke Energy Corporation shares while 352 reduced holdings. 100 funds opened positions while 348 raised stakes. 389.71 million shares or 0.49% less from 391.64 million shares in 2017Q3 were reported. International holds 0.11% or 1.15 million shares in its portfolio. Apriem Advisors has invested 0.07% of its portfolio in Duke Energy Corporation (NYSE:DUK). Town & Country Comml Bank & Dba First Bankers invested in 7,945 shares or 0.33% of the stock. Lbmc Invest Advsrs Ltd Limited Liability Company has 0.14% invested in Duke Energy Corporation (NYSE:DUK) for 9,997 shares. Burke & Herbert Commercial Bank & Tru holds 0.32% in Duke Energy Corporation (NYSE:DUK) or 4,453 shares. Sns Gp Limited Liability accumulated 2,494 shares. Mai Management stated it has 0.03% of its portfolio in Duke Energy Corporation (NYSE:DUK). Stonebridge Cap Advisors Limited Liability Company holds 0.21% or 10,965 shares in its portfolio. Ww Asset Mgmt holds 0.17% of its portfolio in Duke Energy Corporation (NYSE:DUK) for 59,337 shares. Atlantic Limited Liability Corp holds 0.01% of its portfolio in Duke Energy Corporation (NYSE:DUK) for 28,565 shares. 42,400 were accumulated by Louisiana State Employees Retirement System. Bradley Foster & Sargent Ct has 18,543 shares for 0.06% of their portfolio. Nelson Van Denburg Campbell Wealth Gp Ltd owns 0.05% invested in Duke Energy Corporation (NYSE:DUK) for 2,533 shares. Ruggie Cap Group reported 0.01% stake. Liberty Capital Mgmt Inc holds 2,050 shares.

Duke Energy Corporation, together with its subsidiaries, operates as an energy firm in the United States. The company has market cap of $56.51 billion. It operates through three divisions: Electric Utilities and Infrastructure, Gas Utilities and Infrastructure, and Commercial Renewables. It has a 17.95 P/E ratio. The Electric Utilities and Infrastructure segment generates, transmits, distributes, and sells electricity in the Carolinas, Florida, and the Midwest; uses coal, hydroelectric, natural gas, oil, renewable generation, and nuclear fuel to generate electricity; and engages in the wholesale of electricity to municipalities, electric cooperative utilities, and other load-serving entities.

The stock decreased 0.28% or $0.22 during the last trading session, reaching $78.28. About 2.06 million shares traded. Duke Energy Corporation (NYSE:DUK) has declined 6.87% since April 19, 2017 and is downtrending. It has underperformed by 18.42% the S&P500.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $41.64 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 157.23 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It fall, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Exxonmobil Management Inc Tx invested 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The Maryland-based Rock Springs Cap Mngmt Lp has invested 1.16% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Scotia Cap accumulated 17,416 shares. Great West Life Assurance Can holds 220,985 shares or 0.08% of its portfolio. Kepos Lp holds 0.16% or 11,697 shares in its portfolio. Aqr Cap Mgmt Limited Liability Corp invested in 0.24% or 1.52 million shares. Alliancebernstein Limited Partnership accumulated 471,278 shares. Bp Public Ltd Company owns 29,000 shares. Nicholas Investment Prtnrs Ltd Partnership holds 26,384 shares or 0.26% of its portfolio. 165,000 were reported by Bowen Hanes & Co. Arrowstreet Cap Partnership holds 0.43% or 1.20M shares. Norinchukin Financial Bank The invested in 20,219 shares or 0.05% of the stock. Point72 Asset Management Ltd Partnership owns 709,817 shares or 0.46% of their US portfolio. Elk Creek Prtn Limited Liability Corporation has invested 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Natl Bank Of America Corp De, North Carolina-based fund reported 1.40 million shares.

Since October 27, 2017, it had 0 insider purchases, and 43 selling transactions for $122.67 million activity. 3,437 shares valued at $544,730 were sold by Silva Paul M on Tuesday, February 20. $366,350 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Sachdev Amit on Monday, February 26. Shares for $336,345 were sold by Arbuckle Stuart A. The insider MCGLYNN MARGARET G sold $3.25 million. $965,671 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by ALTSHULER DAVID. $580,304 worth of stock was sold by Chodakewitz Jeffrey on Monday, February 5. Shares for $600,680 were sold by Parini Michael.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: